Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as
Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as works-in-progresson panels in its RSNA booth (SCAN 10/11/95).
Hitachi manufactured the single-head 1024RZ and the dual-headT-22 for Summit, which this year merged with Sopha Medical toform SMV (SCAN 6/21/95). SMV decided to deemphasize the Hitachi-madecameras in favor of systems of its own design.
Hitachi has updated the 1024RZ and T-22 cameras and is resubmittinga 510(k) application for them under the trade name SPECTRADigital.Hitachi is also planning to develop a digital variable-angle dual-headgamma camera for release next year.
In MRI, Hitachi will highlight enhancements to its Airis andStratis platforms, introduced at last year's meeting. A new softwarerelease for the open-configuration Airis and the MRP-7000 0.3-teslaconventional magnet will enable the use of new fast scanning andMR angiography packages. On the 1.5-tesla Stratis, Hitachi willshow phased-array coils and multishot echo-planar imaging as works-in-progress.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.